Stockscreener 앱 받기
151.29
0.61%
0.93
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis highlights drug pipeline strength as global healthcare demand grows - Ad-hoc-news.de
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Sahm
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - Barchart.com
Why Does Novartis AG-Sponsored ADR (NYSE:NVS) Track the NYSE Composite? - Kalkine Media
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout - ChartMill
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition - sharewise.com
Novartis to acquire Myricx Bio for $1.5 billion - grafa.com
10 Newly Overvalued Stocks this Week - Morningstar
What's Going on with Vera Therapeutics Stock on Monday? - Sahm
NVSNovartis AG ADR Options - Finviz
NOTA Forecast — Price Target — Prediction for 2027 - TradingView
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States - Sahm
Novartis outlines growth path as pipeline and US exposure support long-term story - ad-hoc-news.de
Novartis stock holds steady after EAACI Rhapsido update. US trading stays in view. - Ad-hoc-news.de
Novartis consensus picture on SIX, analysts keep a neutral view on the stock - Ad-hoc-news.de
Novartis opens the week with a cautious sector backdrop, shares in focus alongside Roche - AD HOC NEWS
Price to earnings forward of Novartis AG Sponsored ADR – MUN:NOTA - TradingView
Novartis oncology partnership with Antares, shares trade near analyst targets - Ad-hoc-news.de
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSC) - TradingView
Novartis focuses on oncology pipeline, shares track SMI pharma peers - Ad-hoc-news.de
907122 Forecast — Price Target — Prediction for 2027 - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSD) - TradingView
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR Actuals & Estimates (BMFBOVESPA:N1VS34) - TradingView
NVS/N Forecast — Price Target — Prediction for 2027 - TradingView
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Sahm
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Novartis highlights pipeline progress, shares trade steadily on NYSE - Ad-hoc-news.de
Novartis AG Stock (NVS) Closed Up by 3.04% on Jun 23: What Signal Does It Send? - TradingKey
Novartis refines India unit strategy, shares in focus on SIX trading - AD HOC NEWS
Novartis strategy highlighted by remibrutinib and Sandoz spin-off, shares steady on SIX - AD HOC NEWS
Why Novartis lets Cosentyx step beyond psoriasis in everyday care - Ad-hoc-news.de
NOVARTIS AG-SPONSORED ADR (NVS) Stock Chart - ChartMill
Cash flow from operating activities of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Enterprise value to EBITDA ratio of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Income Statement – BCBA:NVS.CI - TradingView
2.31%
자본화:
|
볼륨(24시간):